Palvella Therapeutics priced an upsized public offering of 1,600,000 shares at $125.00 per share, raising expected gross proceeds of $200 million1
The company granted underwriters a 30-day option to purchase up to an additional 240,000 shares at the same price1
The offering is expected to close on or about February 27, 2026, subject to customary closing conditions1
Palvella is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations without FDA-approved treatments1
Net proceeds will support development of QTORIN rapamycin and QTORIN pitavastatin programs, as well as general corporate purposes and research and development1
TD Cowen, Cantor, Stifel, Mizuho, LifeSci Capital, Oppenheimer & Co., Canaccord Genuity and H.C. Wainwright & Co. are joint bookrunning managers for the offering1
The offering is registered on Form S-3, which was declared effective by the SEC on January 29, 20261
Sources:
1. https://www.globenewswire.com/news-release/2026/02/26/3245154/0/en/palvella-therapeutics-announces-pricing-of-upsized-public-offering.html